keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B guidelines

keyword
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#1
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29761292/-chronic-hepatitis-b-and-d-delta-current-and-future-treatments
#2
REVIEW
N Wortmann, C Höner Zu Siederdissen, M Cornberg
BACKGROUND: Worldwide, hepatitis B virus (HBV) infection is among the 30 leading causes of death, despite effective vaccination and therapeutic options. Chronic hepatitis delta (coinfection with hepatitis D virus) leads to a rapid disease progression. AIMS: Based on current international guidelines and studies, an overview about present and future therapeutic options for chronic hepatitis B and delta is provided. RESULTS: Therapy with nucleoside or nucleotide analogues leads to nearly complete HBV DNA suppression, which is associated with regression of liver fibrosis and a lower risk for the development of hepatocellular carcinoma...
May 14, 2018: Der Internist
https://www.readbyqxmd.com/read/29743798/inasl-position-statements-on-prevention-diagnosis-and-management-of-hepatitis-b-virus-infection-in-india-the-andaman-statements
#3
REVIEW
Anil Arora, Shivaram P Singh, Ashish Kumar, Vivek A Saraswat, Rakesh Aggarwal, Manisha Bangar, Pradip Bhaumik, Harshad Devarbhavi, Radha K Dhiman, Vinod K Dixit, Ashish Goel, Bhabadev Goswami, Dharmesh Kapoor, Kaushal Madan, Jimmy Narayan, Sandeep Nijhawan, Gaurav Pandey, Ramesh R Rai, Manoj K Sahu, Neeraj Saraf, Shalimar, Thrivikrama Shenoy, Varghese Thomas, Manav Wadhawan
Hepatitis B Virus (HBV) infection is one of the major causes of morbidity, mortality and healthcare expenditure in India. There are no Indian consensus guidelines on prevention, diagnosis and management of HBV infection. The Indian National Association for Study of the Liver (INASL) set up a taskforce on HBV in 2016, with a mandate to develop consensus guidelines for diagnosis and management of HBV infection, relevant to disease patterns and clinical practices in India. The taskforce first identified contentious issues on various aspects of HBV management, which were allotted to individual members of the taskforce who reviewed them in detail...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29726414/separating-business-logic-from-medical-knowledge-in-digital-clinical-workflows-using-business-process-model-and-notation-and-arden-syntax
#4
Jeroen S de Bruin, Klaus-Peter Adlassnig, Harald Leitich, Andrea Rappelsberger
BACKGROUND: Evidence-based clinical guidelines have a major positive effect on the physician's decision-making process. Computer-executable clinical guidelines allow for automated guideline marshalling during a clinical diagnostic process, thus improving the decision-making process. OBJECTIVES: Implementation of a digital clinical guideline for the prevention of mother-to-child transmission of hepatitis B as a computerized workflow, thereby separating business logic from medical knowledge and decision-making...
2018: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/29720066/prevention-of-perinatal-hepatitis-b-virus-transmission-are-we-following-guidelines
#5
Peter G Markey, Helena A White, Alexander T Matthews, Charles R Strebor, Vicki Krause
It is recommended that infants born to women with hepatitis B infection should have serological review following completion of a four dose vaccination schedule. A review was undertaken on 102 neonates who received hepatitis B immunoglobulin to ascertain the proportion that were fully immunised and then followed up. Of the 66 infants for whom data were available, 65 (98.5%) had appropriately received four doses of hepatitis B vaccine in infancy and a further child had received three doses. Only 19/66 (29%; 95%CI: 18-41%) infants had documented follow-up serology results, one of whom was infected and one of whom was immune through clearance of infection...
September 1, 2017: Communicable Diseases Intelligence Quarterly Report
https://www.readbyqxmd.com/read/29720023/direct-acting-antiviral-treatment-of-chronic-hepatitis-c-in-denmark-factors-associated-with-and-barriers-to-treatment-initiation
#6
Christina Sølund, Sofie Hallager, Martin S Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B Krarup, Birgit T Røge, Peer B Christensen, Alex L Laursen, Jan Gerstoft, Erika Bélard, Lone G Madsen, Kristian Schønning, Anders G Pedersen, Jens Bukh, Nina Weis
OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark. MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses...
May 2, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29716442/2017-european-guideline-for-the-screening-prevention-and-initial-management-of-hepatitis-b-and-c-infections-in-sexual-health-settings
#7
Gary Brook, Norbert Brockmeyer, Thijs van de Laar, Sven Schellberg, Andrew J Winter
This guideline updates the 2010 European guideline for the management of hepatitis B and C virus infections. It is primarily intended to provide advice on testing, prevention and initial management of viral hepatitis B and C for clinicians working in sexual health clinical settings in European countries. The guideline is in a new question and answer format based on clinical situations, from which population/intervention/comparison/outcome questions were formulated. Updates cover areas such as epidemiology, point-of-care tests for hepatitis B, hepatitis C risk and 'chemsex', and HIV pre-exposure prophylaxis and hepatitis B...
January 1, 2018: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/29702515/integrated-care-for-the-use-of-direct-acting-antivirals-in-patients-with-chronic-hepatitis-c-and-substance-use-disorder
#8
Jean-Baptiste Trabut, Camille Barrault, Hélène Charlot, Damien Carmona, Anne Bourdel, Mustapha Benslimane, Murielle François, Willy Kini-Matondo, Richard Causse, Françoise Roudot-Thoraval, Christophe Hézode
OBJECTIVES: Since little is currently known about predictors of response to direct-acting antiviral agents (DAAs) in people who inject drugs, we undertook an analysis of patients attending a hepatitis clinic with addiction services (outpatient clinics and inpatient services) to examine the outcomes associated with the treatment of difficult-to-manage patients with substance use. Our experience was based on integrated care. METHOD: A retrospective analysis was undertaken of 50 patients with hepatitis C virus (HCV) and a history of addiction who received treatment with DAAs, according to European guidelines...
April 26, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29696665/using-the-chronic-kidney-disease-guidelines-to-evaluate-the-renal-safety-of-tenofovir-disoproxil-fumarate-in-hepatitis-b-patients
#9
H J Tsai, Y W Chuang, S W Lee, C Y Wu, H Z Yeh, T Y Lee
BACKGROUND: Renal dysfunction remains an issue in tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients. AIM: To evaluate renal safety of TDF according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. METHODS: We retrospectively recruited CHB patients who received either TDF or entecavir (ETV) monotherapy from January 2008 to August 2015. After excluding confounding conditions, 253 patients who received TDF were randomly matched 1:2 with 506 patients who received ETV through the propensity scores, which consisted of age, gender, cirrhosis, chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR)...
April 25, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29682309/australasian-society-for-hiv-viral-hepatitis-and-sexual-health-medicine-hiv-pre-exposure-prophylaxis-clinical-guidelines-update-april-2018
#10
EDITORIAL
Edwina Wright, Andrew Grulich, Katy Roy, Mark Boyd, Vincent Cornelisse, Darren Russell, Darryl O'Donnell, Bill Whittaker, Levinia Crooks, Iryna Zablotska
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine's (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control's PrEP guidelines and are designed to: •Support the prescription of PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials•Assist clinicians in the evaluation of patients who are seeking PrEP•Assist clinicians in commencing and monitoring patients on PrEP including PrEP dosing schedules, management of side-effects and toxicity, use of PrEP in pregnancy and in chronic hepatitis B infection and how to cease PrEP Daily PrEP with co-formulated tenofovir and emtricitabine, used continuously or for shorter periods of time, is recommended in these guidelines as a key HIV-prevention option for men who have sex with men (MSM), transgender men and women, heterosexual men and women, and people who inject drugs (PWID) at substantial risk of HIV acquisition...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29672883/assessment-of-advanced-liver-fibrosis-and-the-risk-for-hepatic-decompensation-in-patients-with-congestive-hepatopathy
#11
REVIEW
Alexander Lemmer, Lisa B Van-Wagner, Daniel Ganger
Congestive hepatopathy (CH) arises from chronically elevated right sided heart pressures transmitted to the liver by passive venous congestion. Over time CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma. Currently there are no evidence-based guidelines to direct appropriate screening or management of patients with CH partly because of the inability of current clinical tools (serum tests, imaging studies, liver stiffness measurements, and liver biopsy) to accurately estimate hepatic fibrosis or the risk for hepatic decompensation...
April 19, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29672472/recommendations-of-the-advisory-committee-on-immunization-practices-for-use-of-a-hepatitis-b-vaccine-with-a-novel-adjuvant
#12
Sarah Schillie, Aaron Harris, Ruth Link-Gelles, José Romero, John Ward, Noele Nelson
Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, administered as a 2-dose series (0, 1 month) for use in persons aged ≥18 years. The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults...
April 20, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29671067/vaccinations-in-pediatric-kidney-transplant-recipients
#13
REVIEW
Thomas G Fox, Corina Nailescu
Pediatric kidney transplant (KT) candidates should be fully immunized according to routine childhood schedules using age-appropriate guidelines. Unfortunately, vaccination rates in KT candidates remain suboptimal. With the exception of influenza vaccine, vaccination after transplantation should be delayed 3-6 months to maximize immunogenicity. While most vaccinations in the KT recipient are administered by primary care physicians, there are specific schedule alterations in the cases of influenza, hepatitis B, pneumococcal, and meningococcal vaccinations; consequently, these vaccines are usually administered by transplant physicians...
April 18, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29663266/hepatitis-b-virus-screening-and-reactivation-in-a-national-va-cohort-of-patients-with-inflammatory-bowel-disease-treated-with-tumor-necrosis-factor-antagonists
#14
Rajesh Shah, Edith Y Ho, Jennifer R Kramer, Peter Richardson, Shubhada Sansgiry, Hashem B El-Serag, Jason K Hou
BACKGROUND: Practice guidelines recommend screening for hepatitis B virus (HBV) infection prior to initiating treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor (anti-TNF) therapy. However, the adherence to these screening guidelines and the clinical outcomes of HBV reactivation following anti-TNF use are not well known. METHODS: This is a retrospective cohort study using the Veterans Health Administration datasets for IBD patients with filled prescriptions for anti-TNFs from 2003 to 2011...
April 16, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29659605/chronic-kidney-disease-in-the-global-adult-hiv-infected-population-a-systematic-review-and-meta-analysis
#15
Udeme E Ekrikpo, Andre P Kengne, Aminu K Bello, Emmanuel E Effa, Jean Jacques Noubiap, Babatunde L Salako, Brian L Rayner, Giuseppe Remuzzi, Ikechi G Okpechi
INTRODUCTION: The widespread use of antiretroviral therapies (ART) has increased life expectancy in HIV patients, predisposing them to chronic non-communicable diseases including Chronic Kidney Disease (CKD). We performed a systematic review and meta-analysis (PROSPERO registration number CRD42016036246) to determine the global and regional prevalence of CKD in HIV patients. METHODS: We searched PubMed, Web of Science, EBSCO and AJOL for articles published between January 1982 and May 2016...
2018: PloS One
https://www.readbyqxmd.com/read/29650086/influenza-pneumococcal-hepatitis-b-and-herpes-zoster-vaccinations
#16
Nadira Husein, Ashen Chetty
No abstract text is available yet for this article.
April 2018: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/29628202/health-status-of-afro-asian-refugees-in-an-italian-urban-area-a-cross-sectional-monocentric-study
#17
R Del Pinto, D Pietropaoli, U Russomando, P Evangelista, C Ferri
OBJECTIVES: The recent sociopolitical events in the Mediterranean and Middle Eastern areas have significantly impacted international migration flows. As disease prevalence and type are different among western and Afro-Asian countries, physicians dealing with refugees should be aware of their specific health needs. We aimed at evaluating the health status and disease history of refugees at their arrival in the urban area of L'Aquila (Italy). STUDY DESIGN: This is a monocentric cross-sectional study...
April 5, 2018: Public Health
https://www.readbyqxmd.com/read/29607054/non-alcoholic-steatofibrosis-nasf-can-independently-predict-mortality-in-patients-with-non-alcoholic-fatty-liver-disease-nafld
#18
Pegah Golabi, Maria Stepanova, Huong T Pham, Rebecca Cable, Nila Rafiq, Haley Bush, Trevor Gogoll, Zobair M Younossi
Background: Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy's invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29603817/utilisation-of-hepatocellular-carcinoma-screening-in-australians-at-risk-of-hepatitis-b-virus-related-carcinoma-and-prescribed-anti-viral-therapy
#19
Suzanne Sheppard-Law, Iryna Zablotska-Manos, Melissa Kermeen, Susan Holdaway, Alice Lee, Jacob George, Amany Zekry, Lisa Maher
AIMS AND OBJECTIVES: This study aimed to investigate HCC screening utilisation and factors associated with utilisation among patients prescribed HBV anti-viral therapy and at risk of HCC. BACKGROUND: The incidence of hepatocellular carcinoma (HCC) has increased in Australia over the past three decades with chronic hepatitis B virus (HBV) infection a major contributor. HCC surveillance programs aim to detect cancers early enabling curative treatment options, longer survival and longer times to recurrence...
March 31, 2018: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/29601854/patients-with-core-antibody-positive-and-surface-antigen-negative-hepatitis-b-anti-hbc-hbsag-on-anti-tnf-therapy-have-a-low-rate-of-reactivation
#20
William T Clarke, Shreya S Amin, Konstantinos Papamichael, Joseph D Feuerstein, Adam S Cheifetz
Anti-TNF agents are widely used to treat immune-mediated disorders. Reactivation of Hepatitis B virus (HBV) is associated with immunosuppressive agents and biologics such as anti-TNF. There are limited data and differing guidelines for patients with negative hepatitis B surface antigen (HBsAg-) but positive antibody to hepatitis B core antigen (anti-HBc+) on anti-TNF with regards to outcomes and need for anti-viral prophylaxis. We examined the prevalence of HBV reactivation in a single-center retrospective cohort study of 120 HBsAg-, anti-HBc+ patients on anti-TNF, totaling 346...
March 27, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
keyword
keyword
99445
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"